FDA grants accelerated approval to Eli Lilly's Lartruvo for soft tissue cancer
The U.S. FDA granted accelerated approval to Lartruvo, or olaratumab, with doxorubicin to treat adults with certain types of soft tissue sarcoma, which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline is an appropriate treatment. "This is the first new therapy approved by the FDA for the initial treatment of soft tissue sarcoma since doxorubicin's approval more than 40 years ago," the agency noted. Lartruvo has "serious risks" including infusion-related reactions and embryo-fetal harm, the FDA added. Lartruvo is marketed by Eli Lilly.